Biogen, Ginkgo partner on enhanced AAV manufacturing for gene therapies

By The Science Advisory Board staff writers

May 21, 2021 -- Biogen and Ginkgo Bioworks will collaborate to develop improved methods for manufacturing recombinant adeno-associated virus (AAV)-based vectors.

Currently, AAV manufacturing is time-consuming and expensive. As a result, it is difficult to develop therapies for diseases that require high doses and with large patient populations. As part of the collaboration, Gingko aims to apply its mammalian cell programming platform to improve the efficiency of AAV-producing plasmid vectors and cell lines, which could accelerate the development of Biogen's gene therapy candidates.

Under the agreement, Biogen will receive access to Ginkgo's proprietary cell programming platform and capabilities. Ginkgo will utilize its bioengineering facilities and resources with the aim of enhancing the AAV production titers of Biogen's gene therapy manufacturing processes. Ginkgo will receive an upfront payment of $5 million and is eligible for potential research, developmental, and commercial milestone payments up to an additional $115 million.

Biogen, Envisagenics collaborate on RNA splicing
Biogen and Envisagenics have announced a new collaboration to advance RNA splicing research within central nervous system diseases.
Biogen set to build new gene therapy manufacturing site
Biogen is planning to build a new manufacturing facility spanning 175,000 sq ft at its base in Research Triangle Park, NC, to support development of its...
ViGeneron, Biogen to develop AAV-based gene therapies for eye disease
ViGeneron and Biogen have signed a global collaboration and licensing agreement to develop and commercialize gene therapy products based on adeno-associated...
Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity...
Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter